Results 141 to 150 of about 17,322 (222)

Block-and-Lock Approaches for HIV Cure: Mechanistic Insights, Challenges, and Emerging Role of CPSF6. [PDF]

Int J Mol Sci
Tolomeo M, Cascio A.
europepmc   +1 more source

Clinical presentation and effectiveness of antiretroviral therapy in newly diagnosed people living with HIV before, during and after the COVID-19 pandemic. [PDF]

BMJ Public Health
Carbone A, Lombardi F, Tiecco G, Iannone V, Logiudice J, Salvo PF, Scoppettuolo G, Gerami R, Cesanelli F, Salvi M, Cingolani A, Castelli F, Di Giambenedetto S, Torti C, Quiros-Roldan E.   +14 more
europepmc   +1 more source

Letter to the editor: When do rare events become expected in HIV drug resistance? [PDF]

Euro Surveill
El-Khatib Z, Wessman M, Sönnerborg A, Fonager J, Zoufaly A, Leierer G, Assadian O, Benka B, Ndeikoundam Ngangro N, Kantor R.   +9 more
europepmc   +1 more source

Therapeutic Opportunities in Infectious Diseases: Highlights from the Society of Medicines Research Symposium, held on March 14th 2013 at the National Heart & Lung Institute, London, UK

, 2013
Collingwood, S P, Pryde, D C, Anderson, RJ, Collingwood, SP, Pryde, DC, Anderson, Rosaleen, Alderton, W K, Alderton, WK   +7 more
core  

Integrase inhibitor-based antiretroviral therapy drives gut microbiota remodeling and immune recovery in HIV infection. [PDF]

Front Med (Lausanne)
Karaca B, Şener A, Kaptan F, Ece D, Örmen B, Caner A.   +5 more
europepmc   +1 more source

To Switch or not to Switch: are there any Antiretroviral Strategies to Attenuate Weight Gain in People with HIV? [PDF]

Curr HIV/AIDS Rep
Debroy P, Lake JE.
europepmc   +1 more source

The LEDGIN GS-9822 inhibits HIV-2 infection and enhances HIV-2 latency. [PDF]

Microbiol Spectr
Bruggemans A, Vansant G, Pellaers E, Van de Velde P, Christ F, Debyser Z.   +5 more
europepmc   +1 more source

Time to Antiretroviral Therapy Initiation After HIV Diagnosis in the Integrase Strand Transfer Inhibitor Era - Nanjing City, Jiangsu Province, China, 2021-2024. [PDF]

China CDC Wkly
Ma C, Yang J, Liu A, Qian Z, Liu Z, Ge Y, Xu Y, Zhu Z, Wei H, Peng Z, Yin G, Hu Z.   +11 more
europepmc   +1 more source

In Vitro Pharmacokinetic Properties of MK-2048, a Potent Drug Candidate for HIV Prevention. [PDF]

Viruses
Zheng R, Valicherla GR, Graebing PW, Zhang J, Hillier SL, Rohan LC.   +5 more
europepmc   +1 more source

HIV-1 drug resistance and associated risk factors in patients with antiretroviral therapy failure in Chongqing, China, 2019-2023. [PDF]

PLoS One
Zhang H, Wu P, Ye W.
europepmc   +1 more source